Previous Close | 10.30 |
Open | 10.35 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 10.35 - 10.44 |
52 Week Range | 6.08 - 14.00 |
Volume | |
Avg. Volume | 20,219 |
Market Cap | 67.933M |
Beta (5Y Monthly) | 1.25 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -24.00 |
Earnings Date | May 09, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 27.67 |
Instil Bio (TIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
DALLAS, March 21, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its fourth quarter and full year 2023 financial results and provided a corporate update. Recent Highlights: Announced entering into a strategic collaboration to develop an autologous folate receptor α (FRα)-CoStAR enhanced TIL for a potential investigator-initiated trial (IIT) in non-small cell lung ca
Instil's (TIL) recent deal with a collaborator to carry out preclinical manufacturing feasibility studies on its ITIL-306 program is a positive.